U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H31NO.C4H4O4
Molecular Weight 417.5384
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DERAMCICLANE FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3

InChI

InChIKey=RFQWRWCCNQNACG-HJYQBBATSA-N
InChI=1S/C20H31NO.C4H4O4/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16;5-3(6)1-2-4(7)8/h6-10,17H,11-15H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t17-,19-,20+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C20H31NO
Molecular Weight 301.4662
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

PubMed

TitleDatePubMed
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.
2001 Jan
Deramciclane (Egis).
2002 Feb
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.
2002 Mar
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.
2002 Mar
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
2003
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
2003 Dec
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.
2004 Apr
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.
2004 Aug
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
2004 Feb
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
2005 Dec
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.
2005 Nov
Role of CYP2E1 in deramciclane metabolism.
2005 Nov
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
2008 Jan
Deramciclane improves object recognition in rats: potential role of NMDA receptors.
2010 Feb
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.
2010 Mar
Patents

Patents

Sample Use Guides

60 mg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:25:41 GMT 2023
Edited
by admin
on Fri Dec 15 15:25:41 GMT 2023
Record UNII
W1183TY0EE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DERAMCICLANE FUMARATE
MI  
Common Name English
EGIS-3886
Code English
DERAMCICLANE FUMARATE [MI]
Common Name English
Code System Code Type Description
FDA UNII
W1183TY0EE
Created by admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
PRIMARY
PUBCHEM
6438165
Created by admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
PRIMARY
CAS
120444-72-6
Created by admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
PRIMARY
MERCK INDEX
m4186
Created by admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY